Organon Set to Join S&P 500; HollyFrontier to Join S&P MidCap 400; Service Properties Trust to Join S&P SmallCap 600

 
 

- Organon & Co. (NYSE: OGN) will be added to the S&P 500 prior to the open of trading on Thursday, June 3 replacing HollyFrontier, which will be removed from the S&P 500 effective prior to the open of trading on Friday, June 4 .

 

HollyFrontier will replace Service Properties Trust (NASD:SVC) in the S&P MidCap 400, and Service Properties Trust will replace Lannett Co Inc. (NYSE:LCI) in the S&P SmallCap 600 also effective prior to the open on June 4 . S&P 500 and 100 constituent Merck & Co (NYSE: MRK) is spinning off Organon (NYSE: OGN) in a transaction expected to be completed post close on Wednesday, June 2 . Post spin-off, Merck will remain in the S&P 500 and 100 indices.  HollyFrontier has a market capitalization more representative of the mid-cap market space. Lannett is no longer representative of the small-cap market space.

 

Following is a summary of the changes that will take place prior to the open of trading on the effective date:

 
 
                                          
 

   Effective Date   

 
 

   Index Name   

 
 

   Action   

 
 

   Company Name   

 
 

   Ticker   

 
 

   GICS Sector   

 
 

   June 3, 2021   

 
 

  S&P 500  

 
 

  Addition  

 
 

  Organon  

 
 

  OGN  

 
 

  Health Care  

 
 

   June 4, 2021   

 
 

  S&P 500  

 
 

  Deletion  

 
 

  HollyFrontier  

 
 

  HFC  

 
 

  Energy  

 
 
 

  S&P MidCap 400  

 
 

  Addition  

 
 

  HollyFrontier  

 
 

  HFC  

 
 

  Energy  

 
 
 

  S&P MidCap 400  

 
 

  Deletion  

 
 

  Service Properties Trust  

 
 

  SVC  

 
 

  Real Estate  

 
 
 

  S&P SmallCap 600  

 
 

  Addition  

 
 

  Service Properties Trust  

 
 

  SVC  

 
 

  Real Estate  

 
 
 

  S&P SmallCap 600  

 
 

  Deletion  

 
 

  Lannett Co  

 
 

  LCI  

 
 

  Health Care  

 
 
 

For more information about S&P Dow Jones Indices, please visit www.spdji.com  

 

ABOUT S&P DOW JONES INDICES

 

S&P Dow Jones Indices is the largest global resource for essential index-based concepts, data and research, and home to iconic financial market indicators, such as the S&P 500® and the Dow Jones Industrial Average®. More assets are invested in products based on our indices than products based on indices from any other provider in the world. Since Charles Dow invented the first index in 1884, S&P DJI has been innovating and developing indices across the spectrum of asset classes helping to define the way investors measure and trade the markets.

 

S&P Dow Jones Indices is a division of S&P Global (NYSE: SPGI), which provides essential intelligence for individuals, companies, and governments to make decisions with confidence. For more information, visit www.spdji.com .

 

  FOR MORE INFORMATION:  

 

  S&P Dow Jones Indices
  index_services@spglobal.com  

 

  Media Inquiries
  spdji.comms@spglobal.com  

 

 Cision View original content: https://www.prnewswire.com/news-releases/organon-set-to-join-sp-500-hollyfrontier-to-join-sp-midcap-400-service-properties-trust-to-join-sp-smallcap-600-301301349.html  

 

SOURCE S&P Dow Jones Indices

 
 

News Provided by PR Newswire via QuoteMedia

The Conversation (0)
Various blister packs with pills and capsules in different colors and shapes.

Trump Signs Sweeping Order to Slash Drug Prices, Pressure Pharma Giants

US President Donald Trump has signed a sweeping executive order aimed at dramatically reducing prices for prescription drugs, vowing to end “foreign free-riding” on American pharmaceutical innovation.

The order directs federal agencies to pressure both drug manufacturers and wealthy foreign countries to bring their prices in line with those paid in the US, or face aggressive trade and regulatory actions.

“In case after case, our citizens pay massively higher prices than other nations pay for the same exact pill, from the same factory, effectively subsidizing socialism abroad with skyrocketing prices at home,” Trump states in the order.

Keep reading...Show less
Blank pill bottle spilling a variety of pharmaceutical pills and capsules.

5 Biggest Pharmaceutical ETFs in 2025

The global pharmaceutical market reached a total value of US$1.38 trillion in 2024, according to Research and Markets, up significantly from the US$888 billion seen just over a decade earlier in 2010.

Experienced and novice investors alike may want to consider pharmaceutical exchange-traded funds (ETFs) as a way to gain exposure to the top pharma companies. Like all ETFs, pharmaceutical ETFs are a good option for those who want to trade a set of assets in the pharmaceutical industry instead of focusing solely on individual pharmaceutical stocks.

The main advantage of a pharmaceutical ETF is the fact that it can provide exposure to an overarching sector, but still trades like a stock. Pharma ETFs also offer less market volatility and lower fees and expenses.

Keep reading...Show less
Invion Limited

Invion Limited

Keep reading...Show less
Large pharmaceutical pill with gold dollar sign in the middle. Stock tickers and charts in the background.

Top 5 Small-cap Pharma Stocks in 2025

Today's pharmaceutical stocks are facing the challenges of government-imposed drug price caps, waning demand for COVID-19 vaccines and global stock market upheaval.

However, the industry's major underlying drivers — higher rates of cancer and chronic disease — are still at play and not expected to dissipate.

The US reigns supreme in the pharma market, both in terms of drug demand and development. In 2024, 50 novel medicines were approved by the US Food and Drug Administration (FDA), compared to 55 such approvals in 2023. Last year's FDA approvals include Eli Lilly and Company's (NYSE:LLY) Alzheimer's disease treatment Kisunla.

Big pharma largely steals the show, but some small- and mid-cap NASDAQ pharma stocks have also made gains.

Keep reading...Show less
Cardiol Therapeutics (TSX:CRDL)

Cardiol Therapeutics Announces Year-End 2024 Update on Operations

Reported positive data from the Phase II MAvERIC-Pilot study investigating the impact of CardiolRx™ administered to patients with symptomatic recurrent pericarditis; results support advancing to the Phase III MAVERIC trial

Completed patient enrollment in the Phase II ARCHER trial evaluating CardiolRx™ in patients
with acute myocarditis, with topline data expected in Q2 2025

Keep reading...Show less

Latest Press Releases

Related News

×